Aileron Therapeutics Files 8-K
Ticker: RNTX · Form: 8-K · Filed: May 1, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | May 1, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $12.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-results, operations
TL;DR
Aileron Therapeutics filed an 8-K on May 1st, reporting operational and financial updates.
AI Summary
Aileron Therapeutics, Inc. filed an 8-K on May 1, 2024, reporting on its results of operations and financial condition, as well as other events. The filing does not contain specific financial figures or details about the 'other events' within the provided text.
Why It Matters
This filing indicates that Aileron Therapeutics has reported on its operational and financial status, and other significant events, which is crucial for investors to understand the company's current standing.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting operational and financial results, without immediate indication of significant negative or positive events.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- May 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38130 (identifier) — Commission File Number
- 13-4196017 (identifier) — IRS Employer Identification No.
- 12407 N. Mopac Expy., Suite 250, #390 Austin, Texas 78758 (address) — Principal Executive Offices
- (737) 802-1989 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are being reported by Aileron Therapeutics?
The provided text of the 8-K filing does not specify the exact financial results or figures being reported.
What are the 'Other Events' mentioned in the filing?
The filing indicates 'Other Events' were reported, but the specific details of these events are not included in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 1, 2024.
What is the principal executive office address for Aileron Therapeutics?
The principal executive office address is 12407 N. Mopac Expy., Suite 250, #390 Austin, Texas 78758.
Under which state was Aileron Therapeutics incorporated?
Aileron Therapeutics, Inc. was incorporated in Delaware.
Filing Stats: 1,394 words · 6 min read · ~5 pages · Grade level 13.5 · Accepted 2024-05-01 08:40:55
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
- $12.0 million — h and cash equivalents of approximately $12.0 million as of March 31, 2024. The estimated c
Filing Documents
- d65915d8k.htm (8-K) — 33KB
- 0001193125-24-126425.txt ( ) — 158KB
- alrn-20240501.xsd (EX-101.SCH) — 3KB
- alrn-20240501_lab.xml (EX-101.LAB) — 18KB
- alrn-20240501_pre.xml (EX-101.PRE) — 11KB
- d65915d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: May 1, 2024 By: /s/ Brian Windsor Brian Windsor, Ph.D. President and Chief Executive Officer